Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | DPP3 | Q9NY33 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 3/20 | 0.37 |
| ▸ | CTSS | P25774 | 3/20 | 0.37 |
| ▸ | CTSK | P43235 | 3/20 | 0.37 |
| ▸ | CTSH | P09668 | 1/20 | 0.37 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
| ▸ | MC4R | P32245 | 2/20 | 0.37 |
| ▸ | MC1R | Q01726 | 2/20 | 0.37 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.37 |
| ▸ | MC3R | P41968 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21168312 | 1.00 | CYP2C19 (0.40) | CYP2C19DPP4CXCR4BCHEDPP3 | |
| SCHEMBL25476873 | 0.94 | DPP4 (0.39) | DPP4CXCR4BCHEDPP3CTSL | |
| SCHEMBL21168335 | 0.88 | MME (0.40) | F2 | |
| SCHEMBL21168334 | 0.88 | MME (0.40) | F2 | |
| SCHEMBL21168290 | 0.84 | FABP4 (0.32) | DPP4 | |
| SCHEMBL21168289 | 0.84 | FABP4 (0.32) | DPP4 | |
| SCHEMBL21168350 | 0.84 | CYP2C19 (0.43) | CYP2C19DPP4BCHEDPP3SMYD3 | |
| SCHEMBL21168357 | 0.84 | CYP2C19 (0.43) | CYP2C19DPP4BCHEDPP3SMYD3 | |
| SCHEMBL21168348 | 0.84 | CYP2C19 (0.43) | CYP2C19DPP4BCHEDPP3SMYD3 | |
| SCHEMBL21168491 | 0.84 | FKBP1A (0.41) | F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230144653-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling Pathways | AURIGENE ONCOLOGY LIMITED (IN) | 2023-05-11 | — | — | US | disclosed |
| US-20230144653-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling Pathways | AURIGENE ONCOLOGY LIMITED (IN) | 2023-05-11 | — | — | US | disclosed |
| US-11560403-B2 | 1,2,4-oxadiazole compounds as inhibitors of CD47 signaling pathways | AURIGENE ONCOLOGY LIMITED (IN) | 2023-01-24 | — | — | US | disclosed |
| US-20210139536-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling Pathways | AURIGENE ONCOLOGY LIMITED (IN) | 2021-05-13 | — | — | US | disclosed |
| US-20190218252-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11560403-B2 | 1,2,4-oxadiazole compounds as inhibitors of CD47 signaling pathways | CD47, HIF1AN, PIK3R5 | CYP2C19 4793/4885DPP4 4769/4885CXCR4 1133/4885 |
| US-20230144653-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling Pathways | CD47, HIF1AN, PIK3R5 | CYP2C19 4760/4885DPP4 4748/4885CXCR4 1150/4885 |
| US-20210139536-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling Pathways | CD47, HIF1AN, PIK3R5 | CYP2C19 4760/4885DPP4 4748/4885CXCR4 1150/4885 |
| US-20190218252-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling | CD47, HIF1AN, PIK3R5 | CYP2C19 4764/4885DPP4 4730/4885CXCR4 1149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.